CLINICAL TRIALS PROFILE FOR XOFLUZA
✉ Email this page to a colleague
All Clinical Trials for XOFLUZA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03959332 ↗ | Study to Assess the Pharmacokinetics, Safety and Tolerability of Baloxavir Marboxil in Healthy Chinese Participants | Completed | Shionogi | N/A | 2019-06-19 | This study will evaluate the pharmacokinetics, safety and tolerability of a single oral dose of baloxavir marboxil (40 mg or 80 mg) in healthy Chinese participants. |
| NCT03959332 ↗ | Study to Assess the Pharmacokinetics, Safety and Tolerability of Baloxavir Marboxil in Healthy Chinese Participants | Completed | Hoffmann-La Roche | N/A | 2019-06-19 | This study will evaluate the pharmacokinetics, safety and tolerability of a single oral dose of baloxavir marboxil (40 mg or 80 mg) in healthy Chinese participants. |
| NCT03969212 ↗ | Study to Assess the Efficacy of Baloxavir Marboxil Versus Placebo to Reduce Onward Transmission of Influenza A or B in Households | Recruiting | Hoffmann-La Roche | Phase 3 | 2019-10-10 | Otherwise healthy index patients (IP) are randomized to either baloxavir marboxil or placebo if their influenza symptoms onset was within 48 hours of screening. Their households are enrolled within 24 hours of randomization if at least 2 household contacts (HHC) have not received influenza vaccine within 6 months of screening and if all HHC screen negative for influenza infection. The main endpoints are assessed based on multiple respiratory swabs, obtained from both IP and HHC up to 9 (+/-1) days post IP randomization, and through the assessment of symptoms. |
| NCT04141930 ↗ | Pilot of Cohort of Households for Influenza Monitoring and Evaluation in Seattle | Completed | Genentech, Inc. | Phase 4 | 2019-11-01 | This study will evaluate a home-based approach to influenza infection control, using prepositioned home-based influenza self-test kits, telemedicine services, and rapid delivery of Xofluza (Baloxavir marboxil) for administration within 48 hours of symptom onset. |
| NCT04141930 ↗ | Pilot of Cohort of Households for Influenza Monitoring and Evaluation in Seattle | Completed | University of Washington | Phase 4 | 2019-11-01 | This study will evaluate a home-based approach to influenza infection control, using prepositioned home-based influenza self-test kits, telemedicine services, and rapid delivery of Xofluza (Baloxavir marboxil) for administration within 48 hours of symptom onset. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for XOFLUZA
Condition Name
Clinical Trial Locations for XOFLUZA
Trials by Country
Clinical Trial Progress for XOFLUZA
Clinical Trial Phase
Clinical Trial Sponsors for XOFLUZA
Sponsor Name
